000212430 001__ 212430
000212430 005__ 20240229154907.0
000212430 0247_ $$2doi$$a10.3390/biom13010095
000212430 0247_ $$2pmid$$apmid:36671480
000212430 0247_ $$2pmc$$apmc:PMC9855798
000212430 0247_ $$2altmetric$$aaltmetric:141912568
000212430 037__ $$aDKFZ-2023-00149
000212430 041__ $$aEnglish
000212430 082__ $$a570
000212430 1001_ $$aBengel, Philipp$$b0
000212430 245__ $$aMetabolomic Profiling in Patients with Different Hemodynamic Subtypes of Severe Aortic Valve Stenosis.
000212430 260__ $$aBasel$$bMDPI$$c2023
000212430 3367_ $$2DRIVER$$aarticle
000212430 3367_ $$2DataCite$$aOutput Types/Journal article
000212430 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1674470273_15650
000212430 3367_ $$2BibTeX$$aARTICLE
000212430 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000212430 3367_ $$00$$2EndNote$$aJournal Article
000212430 520__ $$aSevere aortic stenosis (AS) is a common pathological condition in an ageing population imposing significant morbidity and mortality. Based on distinct hemodynamic features, i.e., ejection fraction (EF), transvalvular gradient and stroke volume, four different AS subtypes can be distinguished: (i) normal EF and high gradient, (ii) reduced EF and high gradient, (iii) reduced EF and low gradient, and (iv) normal EF and low gradient. These subtypes differ with respect to pathophysiological mechanisms, cardiac remodeling, and prognosis. However, little is known about metabolic changes in these different hemodynamic conditions of AS. Thus, we carried out metabolomic analyses in serum samples of 40 AS patients (n = 10 per subtype) and 10 healthy blood donors (controls) using ultrahigh-performance liquid chromatography-tandem mass spectroscopy. A total of 1293 biochemicals could be identified. Principal component analysis revealed different metabolic profiles in all of the subgroups of AS (All-AS) vs. controls. Out of the determined biochemicals, 48% (n = 620) were altered in All-AS vs. controls (p < 0.05). In this regard, levels of various acylcarnitines (e.g., myristoylcarnitine, fold-change 1.85, p < 0.05), ketone bodies (e.g., 3-hydroxybutyrate, fold-change 11.14, p < 0.05) as well as sugar metabolites (e.g., glucose, fold-change 1.22, p < 0.05) were predominantly increased, whereas amino acids (e.g., leucine, fold-change 0.8, p < 0.05) were mainly reduced in All-AS. Interestingly, these changes appeared to be consistent amongst all AS subtypes. Distinct differences between AS subtypes were found for metabolites belonging to hemoglobin metabolism, diacylglycerols, and dihydrosphingomyelins. These findings indicate that relevant changes in substrate utilization appear to be consistent for different hemodynamic subtypes of AS and may therefore reflect common mechanisms during AS-induced heart failure. Additionally, distinct metabolites could be identified to significantly differ between certain AS subtypes. Future studies need to define their pathophysiological implications.
000212430 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000212430 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000212430 650_7 $$2Other$$aheart failure
000212430 650_7 $$2Other$$ahemodynamic subgroups
000212430 650_7 $$2Other$$ametabolic remodeling
000212430 650_7 $$2Other$$ametabolomics
000212430 650_7 $$2Other$$asevere aortic valve stenosis
000212430 7001_ $$aElkenani, Manar$$b1
000212430 7001_ $$aBeuthner, Bo E$$b2
000212430 7001_ $$aPietzner, Maik$$b3
000212430 7001_ $$00000-0002-6705-3241$$aMohamed, Belal A$$b4
000212430 7001_ $$aPollok-Kopp, Beatrix$$b5
000212430 7001_ $$aKrätzner, Ralph$$b6
000212430 7001_ $$aToischer, Karl$$b7
000212430 7001_ $$aPuls, Miriam$$b8
000212430 7001_ $$0P:(DE-He78)039283a5d51058ec79156d0ef67132da$$aFischer, Andreas$$b9$$udkfz
000212430 7001_ $$aBinder, Lutz$$b10
000212430 7001_ $$aHasenfuß, Gerd$$b11
000212430 7001_ $$00000-0001-5134-8347$$aSchnelle, Moritz$$b12
000212430 773__ $$0PERI:(DE-600)2701262-1$$a10.3390/biom13010095$$gVol. 13, no. 1, p. 95 -$$n1$$p95$$tBiomolecules$$v13$$x2218-273X$$y2023
000212430 909CO $$ooai:inrepo02.dkfz.de:212430$$pVDB
000212430 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)039283a5d51058ec79156d0ef67132da$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000212430 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000212430 9141_ $$y2023
000212430 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-07T14:30:28Z
000212430 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-22
000212430 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-22
000212430 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-22
000212430 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-22
000212430 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-22
000212430 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOMOLECULES : 2022$$d2023-10-26
000212430 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000212430 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000212430 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000212430 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:57:05Z
000212430 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:57:05Z
000212430 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:57:05Z
000212430 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000212430 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000212430 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000212430 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000212430 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000212430 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBIOMOLECULES : 2022$$d2023-10-26
000212430 9201_ $$0I:(DE-He78)A270-20160331$$kA270$$lA270 Vaskuläre Signaltransduktion und Krebs$$x0
000212430 980__ $$ajournal
000212430 980__ $$aVDB
000212430 980__ $$aI:(DE-He78)A270-20160331
000212430 980__ $$aUNRESTRICTED